[Federal Register Volume 89, Number 16 (Wednesday, January 24, 2024)]
[Notices]
[Page 4610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01364]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Ben Hurley at 240-669-5092, or 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:

Hybridoma Cell Lines 2A4 and 5B12 Against Puromycin Description of 
Technology

    Protein translation is a central cellular function attracting 
increasing attention from cell biologists as they integrate gene 
product specific information into a systems view of cellular function. 
Scientists at NIAID developed the puromycin-specific antibodies that 
allow for the specific detection of puromycin-containing nascent 
polypeptides via standard immunofluorescence or flow cytometry. The 
resulting ribopuromycylation method (RPM) localizes translation in 
cells and can be applied to any PMY-sensitive eukaryotic or prokaryotic 
cell to study the dynamics of protein synthesis at the cellular level 
and investigate translational processes. It can also be used in vitro 
or in vivo to measure the number of translating ribosomes using flow 
cytometry.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Broad application for studying protein translation.

    Competitive Advantages:

 This technology generates antibodies specific for puromycin 
that can be used to localize translating ribosomes in all cell types.

    Development Stage:

 Research Materials

    Inventors: Jonathan Yewdell, MD, Ph.D., Alexandre David, Ph.D., 
both of NIAID.
    Publications: David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino 
G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by 
ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr 
2;197(1):45-57. doi: 10.1083/jcb.201112145. PMID: 22472439; PMCID: 
PMC3317795.
    Also: PMID 29552591, 27385780, 25311127, 23229864.
    Intellectual Property: HHS Reference No. E-003-2021.
    Licensing Contact: To license this technology, please contact Ben 
Hurley at 240-669-5092, or [email protected], and reference E-
003-2021.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this technology. For collaboration 
opportunities, please contact Ben Hurley at 240-669-5092, or 
[email protected].

    Dated: January 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-01364 Filed 1-23-24; 8:45 am]
BILLING CODE 4140-01-P